Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECTRIMS 2023 | Exploring the predictive value of GFAP in progressive MS

Ahmed Abdelhak, MD, University of California, San Francisco, CA, discusses his work assessing the relationship between glial fibrillary acidic protein (GFAP) and short-term progression independent of relapse activity (PIRA) in primary progressive multiple sclerosis (PPMS). The study, initiated in Germany in 2018, evaluated the potential of GFAP to predict disease progression. Preliminary findings suggest high GFAP levels indicate a higher risk for progression in PPMS patients. While NfL’s effects on MS have been widely researched, understanding GFAP is still in the early stages. This interview took place at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress 2023 in Milan, Italy.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


This study was funded by a grant from the German Multiple Sclerosis Society.